Base de dados : MEDLINE
Pesquisa : C04.588.894 [Categoria DeCS]
Referências encontradas : 5852 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 586 ir para página                         

  1 / 5852 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28886981
[Au] Autor:Blais E; Pichon B; Mampuya A; Antoine M; Lagarde P; Kantor G; Breton-Callu C; Lefebvre C; Gerard M; Aamarcha A; Ozsahin M; Bourhis J; Maingon P; Troussier I; Pourel N
[Ad] Endereço:Service de radiothérapie, institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France. Electronic address: eivind.blais@gmail.com.
[Ti] Título:[Lung dose constraints for normo-fractionated radiotherapy and for stereotactic body radiation therapy].
[Ti] Título:Doses aux organes à risque en radiothérapie conformationnelle et en radiothérapie stéréotaxique : les poumons..
[So] Source:Cancer Radiother;21(6-7):584-596, 2017 Oct.
[Is] ISSN:1769-6658
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Radiation-induced lung disease (RILD) is common after radiation therapy and represents cornerstone toxicities after treatment of thoracic malignancies. From a review of literature, the objective of this article was to summarize clinical and non-clinical parameters associated with the risk of RILD in the settings of normo-fractionated radiotherapy and stereotactic body radiation therapy (SBRT). For the treatment of lung cancers with a normo-fractionated treatment, the mean lung dose (MLD) should be below 15-20Gy. For a thoracic SBRT, V20Gy<10% and MLD<6Gy are recommended. One should pay attention to central tumors and respect specific dose constraints to the bronchial tree. The recent technological improvements may represent an encouraging way to decrease lung toxicities. Finally, our team developed a calculator in order to predict the risk of radiation pneumonitis.
[Mh] Termos MeSH primário: Fracionamento de Dose
Pneumopatias/etiologia
Neoplasias Pulmonares/radioterapia
Pulmão/efeitos da radiação
Órgãos em Risco/efeitos da radiação
Radiocirurgia/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Pneumonite por Radiação/etiologia
Neoplasias Torácicas/radioterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170910
[St] Status:MEDLINE


  2 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28867460
[Au] Autor:Vandendorpe B; Servagi Vernat S; Ramiandrisoa F; Bazire L; Kirova YM
[Ad] Endereço:Département de radiothérapie, institut de cancérologie Jean-Godinot, 1, rue du Général-Koenig, 51100 Reims, France. Electronic address: benjamin7789@hotmail.fr.
[Ti] Título:[Doses to organs at risk in conformational radiotherapy and stereotaxic irradiation: The heart].
[Ti] Título:Doses aux organes à risque en radiothérapie conformationnelle et en radiothérapie en conditions stéréotaxiques : le cÅ“ur..
[So] Source:Cancer Radiother;21(6-7):626-635, 2017 Oct.
[Is] ISSN:1769-6658
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Radiation therapy of breast cancer, Hodgkin lymphoma, lung cancer and others thoracic irradiations induce an ionizing radiation dose to the heart. Irradiation of the heart, associated with patient cardiovascular risk and cancer treatment-induced cardiotoxicity, increase cardiovascular mortality. The long survival after breast or Hodgkin lymphoma irradiation requires watching carefully late treatment toxicity. The over-risk of cardiac events is related to the dose received by the heart and the irradiated cardiac volume. The limitation of cardiac irradiation should be a priority in the planning of thoracic irradiations. Practices have to be modified, using modern techniques to approach of the primary objective of radiotherapy which is to optimize the dose to the target volume, sparing healthy tissues, in this case the heart. We have reviewed the literature on cardiac toxicity induced by conformational tridimensional radiation therapy, intensity-modulated radiation therapy or stereotactic body radiation therapy, in order to evaluate the possibilities to limit cardiotoxicity. Finally, we summarise the recommendations on dose constraints to the heart and coronary arteries.
[Mh] Termos MeSH primário: Coração/efeitos da radiação
Órgãos em Risco/efeitos da radiação
Radiocirurgia
Radioterapia Conformacional
Neoplasias Torácicas/radioterapia
[Mh] Termos MeSH secundário: Doença de Hodgkin
Seres Humanos
Guias de Prática Clínica como Assunto
Radiocirurgia/efeitos adversos
Dosagem Radioterapêutica
Radioterapia Conformacional/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170905
[St] Status:MEDLINE


  3 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28816159
[Au] Autor:Chang JY; Zhang X; Knopf A; Li H; Mori S; Dong L; Lu HM; Liu W; Badiyan SN; Both S; Meijers A; Lin L; Flampouri S; Li Z; Umegaki K; Simone CB; Zhu XR
[Ad] Endereço:Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jychang@mdanderson.org.
[Ti] Título:Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee.
[So] Source:Int J Radiat Oncol Biol Phys;99(1):41-50, 2017 Sep 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pencil-beam scanning (PBS) proton therapy (PT), particularly intensity modulated PT, represents the latest advanced PT technology for treating cancers, including thoracic malignancies. On the basis of virtual clinical studies, PBS-PT appears to have great potential in its ability to tightly tailor the dose to the target while sparing critical structures, thereby reducing treatment-related toxicities, particularly for tumors in areas with complicated anatomy. However, implementing PBS-PT for moving targets has several additional technical challenges compared with intensity modulated photon radiation therapy or passive scattering PT. Four-dimensional computed tomography-based motion management and robust optimization and evaluation are crucial for minimizing uncertainties associated with beam range and organ motion. Rigorous quality assurance is required to validate dose delivery both before and during the course of treatment. Active motion management (eg, breath hold), beam gating, rescanning, tracking, or adaptive planning may be needed for cases involving significant motion or changes in motion or anatomy over the course of treatment.
[Mh] Termos MeSH primário: Movimento
Guias de Prática Clínica como Assunto
Terapia com Prótons/métodos
Radioterapia de Intensidade Modulada/métodos
Neoplasias Torácicas/radioterapia
[Mh] Termos MeSH secundário: Suspensão da Respiração
Esôfago
Tomografia Computadorizada Quadridimensional
Seres Humanos
Pulmão
Órgãos em Risco
Melhoria de Qualidade
Respiração
Treinamento por Simulação/métodos
Neoplasias Torácicas/diagnóstico por imagem
Neoplasias Torácicas/patologia
Carga Tumoral
Incerteza
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE


  4 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28753252
[Au] Autor:George E; Barile M; Tang A; Wiesel O; Coppolino A; Giannopoulos A; Mentzer S; Jaklitsch M; Hunsaker A; Mitsouras D
[Ad] Endereço:Division of Thoracic Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Utility and reproducibility of 3-dimensional printed models in pre-operative planning of complex thoracic tumors.
[So] Source:J Surg Oncol;116(3):407-415, 2017 Sep.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: 3D-printed models are increasingly used for surgical planning. We assessed the utility, accuracy, and reproducibility of 3D printing to assist visualization of complex thoracic tumors for surgical planning. METHODS: Models were created from pre-operative images for three patients using a standard radiology 3D workstation. Operating surgeons assessed model utility using the Gillespie scale (1 = inferior to 4 = superior), and accuracy compared to intraoperative findings. Model variability was assessed for one patient for whom two models were created independently. The models were compared subjectively by surgeons and quantitatively based on overlap of depicted tissues, and differences in tumor volume and proximity to tissues. RESULTS: Models were superior to imaging and 3D visualization for surgical planning (mean score = 3.4), particularly for determining surgical approach (score = 4) and resectability (score = 3.7). Model accuracy was good to excellent. In the two models created for one patient, tissue volumes overlapped by >86.5%, and tumor volume and area of tissues ≤1 mm to the tumor differed by <15% and <1.8 cm , respectively. Surgeons considered these differences to have negligible effect on surgical planning. CONCLUSION: 3D printing assists surgical planning for complex thoracic tumors. Models can be created by radiologists using routine practice tools with sufficient accuracy and clinically negligible variability.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico por imagem
Modelos Anatômicos
Impressão Tridimensional
Sarcoma/diagnóstico por imagem
Neoplasias Torácicas/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Adenocarcinoma/cirurgia
Adulto
Idoso
Feminino
Seres Humanos
Imagem Tridimensional
Imagem por Ressonância Magnética
Masculino
Reprodutibilidade dos Testes
Sarcoma/patologia
Sarcoma/cirurgia
Neoplasias Torácicas/patologia
Neoplasias Torácicas/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170729
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24684


  5 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28734410
[Au] Autor:Martin LW; Wigle DA; Thoracic Surgery Trials Network
[Ad] Endereço:Division of Thoracic Surgery, University of Virginia, Charlottesville, Virginia. Electronic address: lm6yb@virginia.edu.
[Ti] Título:Clinical Trials in Thoracic Surgery: A Report From Ginsberg Day 2017 and Early Risers at STS 2017.
[So] Source:Ann Thorac Surg;104(2):712-713, 2017 Aug.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:No unified source lists clinical trials relevant to general thoracic surgery. This description summarizes the current offerings across the National Cancer Institute Cooperative Group-sponsored clinical trials, and includes trials involving surgery for lung cancer and esophageal cancer, and in some instances, perioperative management of patients undergoing thoracic surgery.
[Mh] Termos MeSH primário: Ensaios Clínicos como Assunto
Sociedades Médicas
Neoplasias Torácicas/cirurgia
Cirurgia Torácica/métodos
Procedimentos Cirúrgicos Torácicos/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170724
[St] Status:MEDLINE


  6 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719469
[Au] Autor:Rooper LM; Sharma R; Li QK; Illei PB; Westra WH
[Ad] Endereço:Departments of *Pathology †Oncology ‡Otolaryngology, The Johns Hopkins University School of Medicine, Baltimore, MD.
[Ti] Título:INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.
[So] Source:Am J Surg Pathol;41(11):1561-1569, 2017 Nov.
[Is] ISSN:1532-0979
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite the importance of recognizing neuroendocrine differentiation when diagnosing tumors of the thoracic cavity, the sensitivity of traditional neuroendocrine markers is suboptimal, particularly for high-grade neuroendocrine carcinomas such as small cell lung carcinoma and large cell neuroendocrine carcinoma. To increase sensitivity, neuroendocrine markers are routinely ordered as panels of multiple immunostains where any single positive marker is regarded as sufficient evidence of neuroendocrine differentiation. Insulinoma-associated protein 1 (INSM1) is a well-validated transcription factor of neuroendocrine differentiation that has only recently been evaluated for diagnostic use. We performed INSM1 immunohistochemistry on a large series of thoracic neuroendocrine and non-neuroendocrine tumors and compared its performance to synaptophysin, chromogranin, and CD56. INSM1 was positive in 94.9% of small cell lung carcinomas and 91.3% of large cell neuroendocrine carcinomas, compared with 74.4% and 78.3% with the combined panel of traditional markers. INSM1 also stained all (100%) of the atypical carcinoids, typical carcinoids and mediastinal paragangliomas, but only 3.3% of adenocarcinomas and 4.2% of squamous cell carcinomas. Overall, INSM1 demonstrated a sensitivity of 96.4% across all grades of thoracic neuroendocrine tumors, significantly more than the 87.4% using the panel of traditional markers (P=0.02). INSM1 is sufficiently sensitive and specific to serve as a standalone first-line marker of neuroendocrine differentiation. A more restrained approach to immunohistochemical analysis of small thoracic biopsies is appropriate given the expanding demand on this limited material for therapeutic biomarker analysis.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/análise
Antígeno CD56/análise
Carcinoma Neuroendócrino/química
Cromograninas/análise
Imuno-Histoquímica
Proteínas Repressoras/análise
Sinaptofisina/análise
Neoplasias Torácicas/química
[Mh] Termos MeSH secundário: Biópsia
Carcinoma Neuroendócrino/patologia
Diferenciação Celular
Diagnóstico Diferencial
Seres Humanos
Gradação de Tumores
Valor Preditivo dos Testes
Neoplasias Torácicas/patologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CD56 Antigen); 0 (Chromogranins); 0 (NCAM1 protein, human); 0 (Repressor Proteins); 0 (SYP protein, human); 0 (Synaptophysin); 147955-03-1 (INSM1 protein, human)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.1097/PAS.0000000000000916


  7 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28643357
[Au] Autor:Lemelle L; Pierron G; Fréneaux P; Huybrechts S; Spiegel A; Plantaz D; Julieron M; Dumoucel S; Italiano A; Millot F; Le Tourneau C; Leverger G; Chastagner P; Carton M; Orbach D
[Ad] Endereço:Department of Pediatric, Adolescent, Young Adults, Institut Curie, Paris, France.
[Ti] Título:NUT carcinoma in children and adults: A multicenter retrospective study.
[So] Source:Pediatr Blood Cancer;64(12), 2017 Dec.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Nuclear protein of the testis (NUT) carcinoma (formerly NUT midline carcinoma) is an aggressive tumor defined by the presence of NUT rearrangement with a poor prognosis. This rare cancer is underdiagnosed and poorly treated. OBJECTIVE: The primary objective of this study was to describe the clinical, radiologic, and biological features of NUT carcinoma. The secondary objective was to describe the various treatments and assess their efficacy. METHODS: This retrospective multicenter study was based on review of the medical records of children and adults with NUT carcinoma with specific rearrangement or positive anti-NUT nuclear staining (>50%). RESULTS: This series of 12 patients had a median age of 18.1 years (ranges: 12.3-49.7 years). The primary tumor was located in the chest in eight patients, the head and neck in three patients, and one patient had a multifocal tumor. Nine patients presented regional lymph node involvement and eight distant metastases. One-half of patients were initially misdiagnosed. Specific NUT antibody was positive in all cases tested. A transient response to chemotherapy was observed in four of 11 patients. Only two patients were treated by surgery and five received radiotherapy with curative intent. At the end of follow-up, only one patient was still in remission more than 12 years after the diagnosis. Median overall survival was 4.7 months (95% confidence interval [CI]: 2.1-17.7). CONCLUSION: NUT carcinoma is an aggressive disease refractory to conventional therapy. Early diagnosis by NUT-specific antibody immunostaining in cases of undifferentiated or poorly differentiated carcinoma to identify the specific rearrangement of NUT gene is useful to propose the optimal therapeutic strategy.
[Mh] Termos MeSH primário: Carcinoma/terapia
Proteínas Nucleares/análise
Proteínas Oncogênicas/análise
[Mh] Termos MeSH secundário: Adolescente
Adulto
Carcinoma/química
Carcinoma/mortalidade
Criança
Feminino
Rearranjo Gênico
Neoplasias de Cabeça e Pescoço/química
Neoplasias de Cabeça e Pescoço/mortalidade
Neoplasias de Cabeça e Pescoço/terapia
Seres Humanos
Masculino
Meia-Idade
Proteínas Nucleares/genética
Proteínas Oncogênicas/genética
Estudos Retrospectivos
Neoplasias Torácicas/química
Neoplasias Torácicas/mortalidade
Neoplasias Torácicas/terapia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (NUT protein, human); 0 (Nuclear Proteins); 0 (Oncogene Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170624
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26693


  8 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28601174
[Au] Autor:Zapala MA; Ho-Fung VM; Lee EY
[Ad] Endereço:Department of Radiology and Biomedical Imaging, Benioff Children's Hospital, University of California, San Francisco, 1975 Fourth Street, San Francisco, CA 94158, USA. Electronic address: Matthew.Zapala@ucsf.edu.
[Ti] Título:Thoracic Neoplasms in Children: Contemporary Perspectives and Imaging Assessment.
[So] Source:Radiol Clin North Am;55(4):657-676, 2017 Jul.
[Is] ISSN:1557-8275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This article focuses on commonly encountered primary lung, airway, mediastinal, and chest wall neoplasms that occur in the pediatric population. Although primary pediatric thoracic neoplasms are rare, imaging is critical in their diagnostic work-up. An overview of the latest imaging techniques specific to evaluate these pediatric thoracic neoplasms is presented across the spectrum of modalities from radiography to PET/MR imaging. In addition, the characteristic imaging appearances of these pediatric primary thoracic neoplasms are discussed with an emphasis on what the radiologist needs to know in routine clinical practice.
[Mh] Termos MeSH primário: Diagnóstico por Imagem/métodos
Neoplasias Torácicas/diagnóstico por imagem
[Mh] Termos MeSH secundário: Criança
Diagnóstico Diferencial
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170612
[St] Status:MEDLINE


  9 / 5852 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535660
[Au] Autor:Wang M; Pan YW; Zhou ZG; Cui Y; Du KP; Li S
[Ad] Endereço:Department of Radiology, the First Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, China.
[Ti] Título:[Clinical Investigation on CT guided cryoablation for treating invasive chest wall or pleural tumors].
[So] Source:Zhonghua Zhong Liu Za Zhi;39(5):395-399, 2017 May 23.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the feasibility and short-term effect of CT guided cryoablation for malignant chest wall or pleural involvement. To follow up 22 patients with chest wall or pleural involvement of various malignancies who underwent cryoablation from January 2012 to January 2015 by conducting postoperative 1-, 3- and 6-month enhanced CT, MRI or PET-CT examinations, respectively, evaluate local curative effect, and observe their progression-free survival (PFS), postoperative pain remission and complications after the cryoablation. A total of 22 patients with 27 lesions received 26 times of argon-helium cryoablation. According to the coverage situation of immediate postoperative ice balls on the lesions, they were divided into a complete coverage group (Group A with 18 patients) and a partial coverage group (Group B with 4 patients). 1 month later, 15 patients' tumors were completely ablated, and 3 had residue and thus received the second cryoablation in Group A, while all patients' tumors had residue in Group B. 3 months later, 17 patients' tumors were completely ablated, and 1 had residue and thus received another cryoablation in Group A, while all patients' residual tumors enlarged in different extent in group B. 6 months later, all lesions were ablated in group A while all patients' residual tumors enlarged in group B. For the 22 patients, their preoperative, and postoperative 1-week, 1-month, 3-month, and 6-month VAS scores were 4.95±0.57, 1.45±0.35, 1.45±0.35, 1.64±1.71, and 2.00±2.35, respectively. The differences in the preoperative, postoperative 1-week, and postoperative 1-month scores are significant statistically ( <0.05), and the difference in the postoperative 1-month and 6-month scores is also with statistical significance ( =0.03). For all patients, their post-operative 1-week, 1-month, 3-monte and 6-month pain remission rates are 90.9%(20/22), 90.9%(20/22), 86.4% (19/22)and 81.8%(18/22), respectively. With a median follow-up of 13.5 months, the median PFS is 7 months. The adverse effect after argon-helium cryoablation involved transitory worsened pain (16 cases), pleural effusion (5 cases, including 3 underwent closed drainage), fever (5 cases), and hemoptysis (3 cases). CT guided argon-helium cryoablation is a safe and effective method to treat malignant chest wall or pleural involvement.
[Mh] Termos MeSH primário: Criocirurgia/métodos
Neoplasias Pleurais/cirurgia
Cirurgia Assistida por Computador/métodos
Neoplasias Torácicas/cirurgia
Parede Torácica/cirurgia
[Mh] Termos MeSH secundário: Argônio/uso terapêutico
Intervalo Livre de Doença
Estudos de Viabilidade
Feminino
Hélio/uso terapêutico
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Neoplasia Residual
Neoplasias Pleurais/patologia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Neoplasias Torácicas/patologia
Tomografia Computadorizada por Raios X
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
206GF3GB41 (Helium); 67XQY1V3KH (Argon)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-3766.2017.05.015


  10 / 5852 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28409885
[Au] Autor:El Madi A; Irtan S; Sauvat F; Zérah M; Schleiermacher G; Galmiche-Roland L; Minard-Colin V; Brisse H; Sarnacki S
[Ad] Endereço:Department of Pediatric Surgery, Fez University Hospital, Fez, Morocco.
[Ti] Título:Long-term results of the transmanubrial osteomuscular-sparing approach for pediatric tumors.
[So] Source:Pediatr Blood Cancer;64(10), 2017 Oct.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The complete and safe resection of pediatric cervicothoracic tumors, mostly represented by neurogenic tumors, remains a surgical challenge because of the complex anatomy of this region. The transmanubrial osteomuscular-sparing approach (TOSA) is an alternative to isolated or combined cervical and thoracic approaches enabling the control of supra-aortic vessels and nerves through the thoracic inlet. METHODS: We retrospectively reviewed the tumor characteristics, completeness of resection, morbidity, and long-term outcome of patients with cervicothoracic tumors removed by TOSA between 2000 and 2012 in our institution. RESULTS: Thirteen patients (7 males, 6 females) underwent surgery at a median age of 72 months (4-188) for neuroblastoma (n = 6), ganglioneuroblastoma (n = 3), rhabdoid tumor (n = 1), melanotic schwannoma (n = 1), chordoma (n = 1), and malignant peripheral nerve sheath tumor in one patient with type 1 neurofibromatosis. The median duration of the procedure was 215 minutes (110-315). Two children presented with postoperative chylothorax that resolved spontaneously. The median duration of hospitalization was 7 days (4-22). At a median follow-up of 39 months (2-159), four patients had died of metastatic relapse (n = 2), locoregional progression (n = 1), and chemotoxicity (n = 1). The patient with melanotic schwannoma was lost to follow-up after a local relapse at 5 months. Long-term morbidity revealed homolateral Claude-Bernard Horner sign and upper limb vasomotor dysfunction in disease-free patients due to mandatory resection of the stellate ganglia. CONCLUSIONS: TOSA is a valuable surgical approach for all cervicothoracic tumors with acceptable long-term morbidity when compared with its complexity. We can therefore recommend TOSA for tumors involving the thoracic inlet.
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço
Neoplasias Neuroepiteliomatosas
Neoplasias Torácicas
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Feminino
Seguimentos
Neoplasias de Cabeça e Pescoço/mortalidade
Neoplasias de Cabeça e Pescoço/patologia
Neoplasias de Cabeça e Pescoço/cirurgia
Seres Humanos
Lactente
Masculino
Neoplasias Neuroepiteliomatosas/mortalidade
Neoplasias Neuroepiteliomatosas/patologia
Neoplasias Neuroepiteliomatosas/cirurgia
Estudos Retrospectivos
Neoplasias Torácicas/mortalidade
Neoplasias Torácicas/patologia
Neoplasias Torácicas/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26527



página 1 de 586 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde